Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
In order for Deloitte to sign off on this Q, they would have had to have fully reviewed the previous 12 months and as such if the put their name to the Q, it’s a defacto full review of company’s dealings
Let’s see if Deloitte come out with audit. I’d rather validation by Deloitte than the OTC as it’s a cesspool.
I’m hearing it was BS and company have attorneys all over it but the real acid test is whether Deloitte back the audit. By the way I believe they will.
With all due respect, show me a link/statement from the QX or the company that says that. I spoke to a guy in the phone is not due diligence and cant be relied on. I’m not suggesting it’s true or untrue but I’d rather have confirmation as opposed to speculation and “a guy told me”
Where can you point to re a compliance issue? Please provide link
You’re statement was “nobody is buying stock” my point was in relation to that comment. Supply and demand is a totally separate conversation but thanks for trying to move off point
Just so there no confusion, all volume is double printed so on a 1.4m day, the actual amount traded is 700k for selling which was bought by smart longs. Fundamentals still the same, just a greedy pig running for the doors before the net closes. Ugly but will end. Still $5 plus by year end. Onwards and upwards from there. Also hearing that the issue for QX was the Hindenburg report. What a corrupt world, funny how selling and QX happened at sane time and related to Hindenburg! Our time will come
For every sell there’s a buy. Market fact. Lot of stock k being tucked away here by smart guys
If you do your homework, you will discover the huge was nearly $3 and we made a killing . Thanks for the concern though.
Grab a chair
I suggest you all sell and give yourself and everyone else peace.
Their site is vague, have they harvested their crop? Where are they re revenues. What’s a valid valuation at present?
What are they doing at present? I’m a shareholders but they have gone ultra dark
Here you go. Only issue is bid/share price.
Updated August 2019
https://listingcenter.nasdaq.com/assets/initialguide.pdf
It’s above $3
The short term issue is per fda mandate, the non fda stem cell market will be severely regulated and while pred are the standard bearers, it will have an impact on revenues. As such the fda want parties in the space to do trials which no doubt pred will do but it will have an impact short term.
The reason big biotech/pharma investors don’t like stem cell is purely because it’s unregulated and as such has huge exposure if something went wrong
The fertility business is wide open for them
And with their IP, the own the endometriosis market, that’s the future growth, especially in China where it’s a huge problem
Maybe that gal is on to something along with the following
Deloitte
Wilson sonsini
ThermoFisher
John sorrintino Pfizer
Mike dey Pfizer
Johnny Nelson president ama
Orin hatch (senator)
Rob Barhorst ex ceo ing
Awards and validated by asrm (largest fertility group in world)
Presentation are esre (largest fertility conference in Europe)
Partnership with preeclampsia foundation (backed by gates foundation)
Partnership with clsa , citic largest bank in Asia trillions under management
Launch Artguide, fertility DX
Approved form 10
Approved and listed on QX
Nasdaq application
Umm
Absolutely and not because they want to, it’s a case of have to. Under fda guidelines, stem cells for regenerative treatments may be shut down late 2020, that forces them down the fda trial route. The good thing is they pred are best in class, have treated thousands of people with no safety issues which may allow them to enter fast tract fda trials.
In the shirt term, it’s all about endometriosis and fertility. Wouldn’t be surprised if we seen spin offs here as big pharma investors see stem cells as a liability. Throw in China and fertility is enough to make everyone extremely happy over the coming years
I love everybody has sources !!!
You’re wrong about stem cell numbers. Rekey contracting so I’m assuming stem cells becoming less important with the company focusing on the fertility business and real growth there.
Stem cell business was always a stop gap and to be honest a real issue for high end biotech/pharma investors as there’s huge risk in stem cell
That’s $20 per share. Absolutely
Ok let me weigh this up.
On one side there’s you (nobody in the message boards)
And on the other side there’s
Deloitte
Wilson sonsini
ThermoFisher
John sorrintino Pfizer
Mike dey Pfizer
Johnny Nelson president ama
Orin hatch (senator)
Rob Barhorst ex ceo ing
Awards and validated by asrm (largest fertility group in world)
Presentation are esre (largest fertility conference in Europe)
Partnership with preeclampsia foundation (backed by gates foundation)
Partnership with clsa , citic largest bank in Asia trillions under management
Launch Artguide, fertility DX
Approved form 10
Approved and listed on QX
Nasdaq application
Umm thought one
Look at all your statements re what the management got wrong and show me where the company put out information to support your statement? They company isn’t responsible for people spouting rumors that in turn people project as fact. That is down to people trying to be more important than they are for their egos.
On your point in nasdaq, show me where it was mishandled? The company had no control over the Hindenburg piece which was a huge hit to nasdaq.
The process states on June 21 for nasdaq upon acceptance of the form 10 . That’s approx 4 months ago. Hardy a disaster. What is a disaster is the unrealistic expectations. They people who don’t understand the process have.
It’s a process and it will finish but giving everything that happened, (outside of company’s control) the fact we are still in the process at all is a positive.
QX, Deloitte are all positive moves and will make it easier to Nasdaq to make the move.
Your right re the QX move should have happened months ago and that should have been done. That’s down to the advice the company was getting and the noises from nasdaq. Hindenburg did damage re all that but the corner has been turned and the actions of the company over the last few weeks suggest a much more experienced hand at work which is good news for all
And you still don’t get it! It’s not about earnings! The earnings are irrelevant. They were a stop gap. Short term earnings not important as they are moving away from stem cells to the diagnostics and eventually therapeutics. As such they will be judged earnings wise at the end 2020 beginning 2021. Prior to that it’s all about potential.
The wild card is China and possible big deals that have been mentioned here before. If any of those happen then the numbers being touted may seem small.
Also without being a downer for some of you guys. I noticed Monday /Tuesday some of you were beating management up and saying how terrible the world was. Now the same people are high fiving and and the world is all roses. In both cases you’re wrong. The fundamentals are still exactly the same. The only difference is perception and your attitude.
It’s important to keep perspective no matter what way the stock is. Understand the fundamentals, read the press, know what you own and then understand that with a bit of patience’s, this may be the best trade/investment you ever make.
It’s already trading on QX as off today and re naked short. It’s a myth, impossible to quantify or prove. It’s irrelevant as the only thing that should be focused on is fundamentals, that trumps everything else. Price is temporary, value is permanent
Giving that we are assuming, you would have to assume that moving that data across takes time and as LifeSci get up to speed, those things will happen
You obviously didn’t see they changed PR teams and as such they probably don’t have your details!
I’m not a day trader, I’m an investor so say to day is irrelevant to me. As an investment this is the one to be in
Are you 4 ? Bid ask spread is always skued pre market! It’s the residual from day before.
You’re FOS
Glad you approve.. all steps baby . Deloitte , QX . All roads leading to Nasdaq.
I would assume so. Normally OTCQX will put out PR so I assume press pre market
OTCQX FOR PRED
Big step in the right direction for the company. NASDAQ won’t be far behind this I’d imagine
https://www.otcmarkets.com/stock/PRED/quote
Complete BS. There is nobody going after the shorts etc. this story has been retold time and time again and shorts don’t lose nor are they ever taken to task. Dams is a short nut who sees shorts everywhere and is completely obsessed.
This story is based on a great company, don’t waste your time or energy on something that is never going to happen
Each to your own, if you believe that then sell. Whether you go or stay isn’t relevant to anyone outside you. I buy for investment purposes and as such, this is a gimme. You obviously bought in hype and didn’t do any homework. Education is power so go learn what this company is, then make a decision based on that, not in what you heard or somebody told you
Go look up the Nasdaq and you will understand it’s a process that runs until they make a decision. Question answer. When they have all questions asked and answered then they approve or deny. Until either IOC those happen the company has nothing to report . Capiche ?
Here’s some basic info for you as you seem to be struggling
Otc companies cannot put out revenue projections etc as it’s deem promotional
Everything pred is doing is by the book. This the PRs and Ks are on the cautious side
The company has communicated extremely well. 28 PRs in 10 months
Rather than attack somebody who has taken the time and expense to go and validate everything, why don’t you do the same?
First post and it’s nonsense!
Good with the private messages !! Keep laughing. It’s going to be real funny soon